title: Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?
abstract: Adjuvant endocrine therapy improves recurrence and survival rates, but has side effects and is inconvenient. The aim of this study was to determine the preferences of premenopausal women who had adjuvant endocrine therapy in a randomised trial. In all, 85 (or eighty-five) women completed semistructured interviews 6-30 months after finishing adjuvant endocrine therapy. Hypothetical scenarios based on known potential survival times (5 or 15 years) and rates (60% or 80% at 5 years) without adjuvant endocrine therapy were used to determine the smallest gains women judged necessary to make their adjuvant endocrine therapy worthwhile. Although a third of the women considered gains of 1% in survival rates or 6 months in survival times sufficient to make their adjuvant endocrine therapy worthwhile, more than half the women required gains of at least 5% in survival rates or 3 years in survival time as necessary to make adjuvant endocrine therapy worthwhile. Larger benefits were required by women who had longer treatment, worse side effects, and by those who were treated with goserelin alone. The route of administration (tablet vs injection) did not affect preferences and some women judged small benefits sufficient to make their adjuvant endocrine therapy worthwhile, but many women required larger benefits than their counterparts in similar studies of preferences for adjuvant chemotherapy.
authors.affiliation: NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
authors.forename: V M
authors.initials: VM
authors.lastname: Duric
authors.forename: L J
authors.initials: LJ
authors.lastname: Fallowfield
authors.forename: C
authors.initials: C
authors.lastname: Saunders
authors.forename: J
authors.initials: J
authors.lastname: Houghton
authors.forename: A S
authors.initials: AS
authors.lastname: Coates
authors.forename: M R
authors.initials: MR
authors.lastname: Stockler
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005260:Female; D006306:Health Surveys; D006801:Humans; D008875:Middle Aged; D017060:Patient Satisfaction; D017697:Premenopause; D011379:Prognosis; D013534:Survival
chemical_list: D018931:Antineoplastic Agents, Hormonal